Tirzepatide is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, while other medications in this class activate only GLP-1 receptors
A patient with favorable GLP1R variants may see robust appetite suppression at lower doses, while another with FTO rs9939609 variant patterns might benefit from earlier dose escalation
Data Availability Statement The data presented in this study are available in Table 2, Table 3, Table 4, Table 5, Table 6 and Table 7
It works by mimicking the action of a hormone called GLP-1, which helps regulate blood sugar levels and suppress appetite
In rare cases, however, a client may opt for saline tattoo removal instead
At $1,000-2,000 per month, it is only available to those with substantial resources, so does a drug like this violate the spirit of sport